QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
QQQ   312.83 (-3.49%)
AAPL   120.99 (-3.48%)
MSFT   228.99 (-2.37%)
FB   254.69 (-3.64%)
GOOGL   2,015.95 (-3.26%)
AMZN   3,057.16 (-3.24%)
TSLA   682.22 (-8.06%)
NVDA   532.30 (-8.22%)
BABA   240.18 (-4.06%)
CGC   33.21 (-6.71%)
GE   12.76 (-2.74%)
MU   88.12 (-4.76%)
NIO   46.81 (-9.74%)
AMD   82.42 (-5.20%)
T   28.63 (-2.55%)
F   11.76 (-4.16%)
ACB   10.82 (-7.04%)
DIS   190.98 (-3.31%)
BA   216.45 (-5.62%)
NFLX   546.70 (-1.21%)
BAC   35.93 (-1.24%)
Log in
NYSE:BHC

Bausch Health Companies Competitors

$31.28
+0.23 (+0.74 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.64
Now: $31.28
$31.57
50-Day Range
$22.34
MA: $27.46
$32.03
52-Week Range
$11.15
Now: $31.28
$32.50
Volume4.95 million shs
Average Volume4.59 million shs
Market Capitalization$11.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Competitors

Bausch Health Companies (NYSE:BHC) Vs. ALXN, BGNE, GMAB, HZNP, CTLT, and RPRX

Should you be buying BHC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Bausch Health Companies, including Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), Catalent (CTLT), and Royalty Pharma (RPRX).

Bausch Health Companies (NYSE:BHC) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Bausch Health Companies and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Alexion Pharmaceuticals16.32%23.16%14.76%

Insider & Institutional Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Bausch Health Companies and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.29$-1,788,000,000.00$4.437.06
Alexion Pharmaceuticals$4.99 billion6.77$2.40 billion$9.7415.78

Alexion Pharmaceuticals has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Bausch Health Companies and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies05702.58
Alexion Pharmaceuticals017712.36

Bausch Health Companies presently has a consensus price target of $30.1818, suggesting a potential downside of 3.51%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential downside of 0.34%. Given Alexion Pharmaceuticals' higher probable upside, analysts clearly believe Alexion Pharmaceuticals is more favorable than Bausch Health Companies.

Volatility & Risk

Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Bausch Health Companies on 9 of the 14 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Bausch Health Companies (NYSE:BHC) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and target prices for BeiGene and Bausch Health Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BeiGene12402.43
Bausch Health Companies05702.58

BeiGene presently has a consensus target price of $308.1667, suggesting a potential downside of 6.54%. Bausch Health Companies has a consensus target price of $30.1818, suggesting a potential downside of 3.51%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, analysts clearly believe Bausch Health Companies is more favorable than BeiGene.

Volatility & Risk

BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares BeiGene and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BeiGene-569.22%-56.81%-39.93%
Bausch Health Companies-23.92%173.20%4.21%

Valuation and Earnings

This table compares BeiGene and Bausch Health Companies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeiGene$428.21 million70.44$-948,630,000.00($15.80)-20.87
Bausch Health Companies$8.60 billion1.29$-1,788,000,000.00$4.437.06

BeiGene has higher earnings, but lower revenue than Bausch Health Companies. BeiGene is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bausch Health Companies beats BeiGene on 12 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Profitability

This table compares Bausch Health Companies and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Genmab A/S50.99%34.40%30.67%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bausch Health Companies and Genmab A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies05702.58
Genmab A/S34702.29

Bausch Health Companies presently has a consensus target price of $30.1818, indicating a potential downside of 3.51%. Genmab A/S has a consensus target price of $42.1429, indicating a potential upside of 25.13%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Bausch Health Companies.

Earnings & Valuation

This table compares Bausch Health Companies and Genmab A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.29$-1,788,000,000.00$4.437.06
Genmab A/S$804.57 million27.44$324.68 million$0.5166.04

Genmab A/S has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 6.2% of Genmab A/S shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Bausch Health Companies beats Genmab A/S on 7 of the 13 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Bausch Health Companies (NYSE:BHC) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Horizon Therapeutics Public and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Bausch Health Companies-23.92%173.20%4.21%

Earnings & Valuation

This table compares Horizon Therapeutics Public and Bausch Health Companies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.38$573.02 million$1.9446.69
Bausch Health Companies$8.60 billion1.29$-1,788,000,000.00$4.437.06

Horizon Therapeutics Public has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Horizon Therapeutics Public and Bausch Health Companies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Bausch Health Companies05702.58

Horizon Therapeutics Public presently has a consensus price target of $101.8889, indicating a potential upside of 12.50%. Bausch Health Companies has a consensus price target of $30.1818, indicating a potential downside of 3.51%. Given Horizon Therapeutics Public's stronger consensus rating and higher probable upside, research analysts clearly believe Horizon Therapeutics Public is more favorable than Bausch Health Companies.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Horizon Therapeutics Public beats Bausch Health Companies on 9 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Catalent (NYSE:CTLT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Institutional & Insider Ownership

62.9% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 97.8% of Catalent shares are owned by institutional investors. 12.1% of Bausch Health Companies shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Bausch Health Companies and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Catalent9.25%14.20%4.83%

Volatility and Risk

Bausch Health Companies has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Bausch Health Companies and Catalent, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies05702.58
Catalent01702.88

Bausch Health Companies presently has a consensus price target of $30.1818, suggesting a potential downside of 3.51%. Catalent has a consensus price target of $121.3750, suggesting a potential upside of 8.13%. Given Catalent's stronger consensus rating and higher possible upside, analysts clearly believe Catalent is more favorable than Bausch Health Companies.

Valuation & Earnings

This table compares Bausch Health Companies and Catalent's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.29$-1,788,000,000.00$4.437.06
Catalent$3.09 billion6.18$173 million$1.8859.71

Catalent has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Summary

Catalent beats Bausch Health Companies on 9 of the 13 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Bausch Health Companies (NYSE:BHC) are both large-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Bausch Health Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Bausch Health Companies05702.58

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 10.33%. Bausch Health Companies has a consensus target price of $30.1818, suggesting a potential downside of 3.51%. Given Royalty Pharma's higher probable upside, research analysts plainly believe Royalty Pharma is more favorable than Bausch Health Companies.

Profitability

This table compares Royalty Pharma and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Bausch Health Companies-23.92%173.20%4.21%

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 12.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Royalty Pharma and Bausch Health Companies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Bausch Health Companies$8.60 billion1.29$-1,788,000,000.00$4.437.06

Royalty Pharma has higher earnings, but lower revenue than Bausch Health Companies.

Summary

Bausch Health Companies beats Royalty Pharma on 7 of the 9 factors compared between the two stocks.


Bausch Health Companies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$153.65+0.5%$33.78 billion$4.99 billion35.90
BeiGene logo
BGNE
BeiGene
1.1$329.73+1.6%$30.16 billion$428.21 million-16.32Upcoming Earnings
Analyst Report
News Coverage
GMAB
Genmab A/S
1.7$33.68+4.3%$22.08 billion$804.57 million26.11Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$90.57+5.4%$19.99 billion$1.30 billion24.75Earnings Announcement
Insider Selling
News Coverage
Catalent logo
CTLT
Catalent
1.5$112.25+2.6%$19.11 billion$3.09 billion71.50
Royalty Pharma logo
RPRX
Royalty Pharma
1.6$47.02+0.4%$18.25 billionN/A0.00Analyst Revision
CureVac logo
CVAC
CureVac
0.6$92.97+5.6%$17.38 billionN/A0.00Analyst Downgrade
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$146.59+3.4%$17.15 billion$219.75 million-18.72Analyst Downgrade
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$31.73+0.6%$14.97 billion$3.07 billion-55.67Earnings Announcement
Analyst Downgrade
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$81.76+1.9%$14.84 billion$1.70 billion18.71Insider Selling
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$11.00+2.9%$12.01 billion$16.89 billion-2.99
Grifols logo
GRFS
Grifols
1.2$16.37+4.0%$11.26 billion$5.71 billion14.62Gap Down
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$60.61+0.6%$10.04 billion$2.32 billion50.09
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.4$195.60+3.7%$9.83 billion$3.34 million-25.40News Coverage
BBIO
BridgeBio Pharma
1.6$65.13+3.5%$9.69 billion$40.56 million-19.10Upcoming Earnings
Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$170.74+1.6%$9.51 billion$2.16 billion53.86Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$136.25+4.8%$9.12 billion$103.71 million-31.04Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.2$147.39+6.5%$8.56 billion$12.98 million-48.64Upcoming Earnings
High Trading Volume
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$82.20+3.4%$8.53 billion$87.99 million-97.86
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$158.66+3.0%$8.47 billion$14.98 million-19.33
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$47.31+2.9%$7.52 billion$339.08 million-27.51Earnings Announcement
Analyst Report
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$168.80+2.9%$7.50 billion$1.45 billion15.97Earnings Announcement
Analyst Report
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.2$53.41+5.2%$7.47 billion$1.12 billion111.27Earnings Announcement
Analyst Report
News Coverage
SDGR
Schrödinger
1.3$104.50+6.2%$7.26 billion$85.54 million0.00Upcoming Earnings
Insider Selling
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$85.25+1.1%$6.73 billion$380.83 million-10.90Upcoming Earnings
AVIR
Atea Pharmaceuticals
1.7$81.29+1.6%$6.72 billionN/A0.00
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$214.85+0.1%$6.67 billion$311.33 million-124.91Analyst Report
Analyst Revision
Allakos logo
ALLK
Allakos
1.4$118.26+2.3%$6.21 billionN/A-43.16Analyst Report
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$43.50+3.6%$5.72 billion$150,000.00-20.52Upcoming Earnings
TPTX
Turning Point Therapeutics
1.9$116.91+1.0%$5.63 billionN/A-33.31Upcoming Earnings
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.09+1.8%$5.57 billion$66.51 million17.73Analyst Report
Analyst Revision
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$85.14+0.6%$5.57 billion$1.00 billion-12.90Analyst Upgrade
Gap Down
Perrigo logo
PRGO
Perrigo
2.6$40.78+2.2%$5.57 billion$4.84 billion-679.55Upcoming Earnings
Dividend Increase
Unusual Options Activity
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$32.18+4.2%$5.43 billionN/A0.00Upcoming Earnings
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$97.15+1.7%$5.18 billion$1.11 billion31.24Analyst Upgrade
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.6$83.15+3.1%$4.98 billionN/A-6.78Upcoming Earnings
News Coverage
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21+0.0%$4.75 billion$26.69 million-46.12News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$79.49+0.8%$4.62 billion$806.43 million-11.26Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$65.87+2.6%$4.56 billion$36.13 million-98.31Upcoming Earnings
News Coverage
FibroGen logo
FGEN
FibroGen
1.4$49.86+6.3%$4.54 billion$256.58 million-19.10Upcoming Earnings
Analyst Downgrade
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$83.45+1.9%$4.34 billion$6.87 million-8.06Earnings Announcement
Analyst Report
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.80+2.2%$4.34 billion$204.89 million-37.25Upcoming Earnings
News Coverage
IMAB
I-Mab
0.9$58.48+0.8%$4.21 billion$4.31 million-2.02Analyst Report
High Trading Volume
Gap Down
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$123.19+2.5%$4.20 billion$26.52 million-10.85Upcoming Earnings
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$22.44+1.5%$4.03 billion$114.62 million-9.05Analyst Downgrade
Analyst Revision
Insmed logo
INSM
Insmed
1.2$37.16+7.7%$3.79 billion$136.47 million-14.29Earnings Announcement
News Coverage
Gap Up
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$55.19+4.4%$3.77 billion$306.98 million-7.90News Coverage
LEGN
Legend Biotech
1.2$27.48+2.8%$3.63 billion$64.39 million0.00Gap Down
ARVN
Arvinas
2.0$73.94+3.0%$3.58 billion$42.98 million-28.88
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$50.29+5.2%$3.49 billion$117.91 million-10.20Earnings Announcement
News Coverage
This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.